DUBLIN–(BUSINESS WIRE)–The “Global
Pharmaceutical Partnering Terms and Agreements 2014-2019: Deal Trends,
Players and Financials” report has been added to ResearchAndMarkets.com’s
This report provides a detailed understanding and analysis of how and
why companies enter Pharmaceutical partnering deals.
This report provides details of the latest Pharmaceutical agreements
announced in the life sciences since 2014.
The report takes the reader through a comprehensive review
Pharmaceutical deal trends, key players, top deal values, as well as
deal financials, allowing the understanding of how, why and under what
terms, companies are entering Pharmaceutical partnering deals.
The report presents financial deal term values for Pharmaceutical deals,
listing by headline value, upfront payments, milestone payments and
royalties, enabling readers to analyse and benchmark the financial value
The middle section of the report explores the leading dealmakers in the
Pharmaceutical partnering field; both the leading deal values and most
active Pharmaceutical dealmaker companies are reported allowing the
reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 8,000 online deal
records of actual Pharmaceutical deals, as disclosed by the deal
parties, are included towards the end of the report in a directory
format – by company A-Z, stage of development, deal type, therapy focus,
and technology type – that is easy to reference. Each deal record in the
report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as
submitted to the Securities Exchange Commission by companies and their
partners. Whilst many companies will be seeking details of the payment
clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases
and databases do not.
The initial chapters of this report provide an orientation of
Pharmaceutical dealmaking. Chapter 1 provides an introduction to the
report, whilst chapter 2 provides an overview of the trends in
Pharmaceutical dealmaking since 2014, including details of headline,
upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Pharmaceutical deals since
2014. Deals are listed by headline value. Where the deal has an
agreement contract published at the SEC a link provides online access to
Chapter 4 provides a comprehensive listing of the top 50 most active
companies in Pharmaceutical dealmaking with a brief summary followed by
a comprehensive listing of Pharmaceutical deals announded by that
company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Pharmaceutical
partnering deals signed and announced since Jan 2014, where a contract
document is available in the public domain. Each deal title links via
Weblink to an online version of the deal record and contract document,
providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Pharmaceutical
partnering deals signed and announced since Jan 2014. The chapter is
organized by specific technology type. Each deal title links via Weblink
to an online version of the deal record and where available, the
contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by
Pharmaceutical partnering company A-Z, stage of development, deal type,
and therapy focus. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document,
providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in Pharmaceutical partnering and dealmaking since
In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of Pharmaceutical technologies and products.
- In-depth understanding of Pharmaceutical deal trends since 2014
- Access to headline, upfront, milestone and royalty data
Analysis of the structure of Pharmaceutical agreements with real life
Detailed access to actual Pharmaceutical contracts entered into by
leading biopharma companies
- Identify most active Pharmaceutical dealmakers since 2014
Insight into terms included in a Pharmaceutical partnering agreement,
with real world examples
- Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal
terms for partner companies
Global Pharmaceutical Partnering 2014-2019: Deal trends, players,
financials and forecasts is intended to provide the reader with an
in-depth understanding and access to Pharmaceutical trends and structure
of deals entered into by leading companies worldwide.
Pharmaceutical Partnering Terms and Agreements includes:
Trends in Pharmaceutical dealmaking in the biopharma industry since
- Analysis of Pharmaceutical deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Pharmaceutical deals
- Access to Pharmaceutical contract documents
- Leading Pharmaceutical deals by value since 2014
- Most active Pharmaceutical dealmakers since 2014
In Global Pharmaceutical Partnering 2014-2019: Deal trends,
players, financials and forecasts, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy access
to each contract document on demand.
The Global Pharmaceutical Partnering 2014-2019: Deal trends, players,
financials and forecasts report provides comprehensive access to
available deals and contract documents for over 8,000 Pharmaceutical
Analyzing actual contract agreements allows assessment of the
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sub-licensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
For more information about this report visit https://www.researchandmarkets.com/research/f893kr/pharmaceutical?w=4
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900